Literature DB >> 33091263

Measuring Outcomes in Psoriatic Arthritis.

Alexis Ogdie1, Laura C Coates2, Philip Mease3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33091263      PMCID： PMC8528225          DOI： 10.1002/acr.24242

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  127 in total

1.  Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study.

Authors:  William Tillett; Gavin Shaddick; Ayman Askari; Annie Cooper; Paul Creamer; Gavin Clunie; Philip S Helliwell; Lesley Kay; Eleanor Korendowych; Suzanne Lane; Jonathan Packham; Ragai Shaban; Lyn Williamson; Neil McHugh
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

2.  The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy.

Authors:  Elsa Vieira-Sousa; Helena Canhão; Pedro Alves; Ana Maria Rodrigues; Filipa Teixeira; José Tavares-Costa; Alexandra Bernardo; Sofia Pimenta; Fernando Pimentel-Santos; João L Gomes; Renata Aguiar; Taciana Videira; Patrícia Pinto; Cristina Catita; Helena Santos; Joana Borges; Graça Sequeira; Célia Ribeiro; Lídia Teixeira; Pedro Ávila-Ribeiro; Fernando M Martins; Ruy M Ribeiro; João Eurico Fonseca
Journal:  Acta Reumatol Port       Date:  2018 Apr-Jun       Impact factor: 1.290

Review 3.  Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.

Authors:  Amanda Robinson; Marisa Kardos; Alexandra B Kimball
Journal:  J Am Acad Dermatol       Date:  2011-10-29       Impact factor: 11.527

4.  A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

Authors:  Laure Gossec; Maarten de Wit; Uta Kiltz; Juergen Braun; Umut Kalyoncu; Rossana Scrivo; Mara Maccarone; Laurence Carton; Kati Otsa; Imre Sooäär; Turid Heiberg; Heidi Bertheussen; Juan D Cañete; Anselm Sánchez Lombarte; Andra Balanescu; Alina Dinte; Kurt de Vlam; Josef S Smolen; Tanja Stamm; Dora Niedermayer; Gabor Békés; Douglas Veale; Philip Helliwell; Andrew Parkinson; Thomas Luger; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2014-06       Impact factor: 19.103

5.  Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Authors:  Elizabeth G Araujo; Matthias Englbrecht; Sabrina Hoepken; Stephanie Finzel; Eleni Kampylafka; Arnd Kleyer; Sarah Bayat; Verena Schoenau; Axel Hueber; Juergen Rech; Georg Schett
Journal:  Semin Arthritis Rheum       Date:  2018-06-13       Impact factor: 5.532

6.  Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.

Authors:  April W Armstrong; Kory Parsi; Clayton W Schupp; Philip J Mease; Kristina C Duffin
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

7.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.

Authors:  Dafna D Gladman; Robert D Inman; Richard J Cook; Walter P Maksymowych; Jurgen Braun; John C Davis; Robert B M Landewé; Philip Mease; Joachim Brandt; Ruben Burgos Vargas; Vinod Chandran; Philip Helliwell; Arthur Kavanaugh; Finbar D O'Shea; Muhammad A Khan; Nicolo Pipitone; Proton Rahman; John D Reveille; Millicent A Stone; William Taylor; Douglas J Veale; Desirée van der Heijde
Journal:  J Rheumatol       Date:  2007-08       Impact factor: 4.666

8.  Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps.

Authors:  William Tillett; Neil McHugh; Ana-Maria Orbai; Alexis Ogdie; Ying Ying Leung; Laura C Coates; Philip J Mease; Dafna D Gladman; Mel Brooke; Jon Packham; Denis O'Sullivan; Oliver FitzGerald; Philip S Helliwell
Journal:  J Rheumatol Suppl       Date:  2020-06

Review 9.  The Definition and Measurement of Axial Psoriatic Arthritis.

Authors:  Ennio Lubrano; Wendy Joanne Parsons; Antonio Marchesoni; Ignazio Olivieri; Salvatore D'Angelo; Alberto Cauli; Francesco Caso; Luisa Costa; Raffaele Scarpa; Luca Brunese
Journal:  J Rheumatol Suppl       Date:  2015-11

10.  Remission criteria and activity indices in psoriatic arthritis.

Authors:  M L Acosta Felquer; L Ferreyra Garrott; J Marin; E Catay; M Scolnik; V Scaglioni; S Ruta; J Rosa; E R Soriano
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980
View more
  2 in total

1.  Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe.

Authors:  A Ogdie; W Tillett; N Booth; O Howell; A Schubert; S Peterson; S D Chakravarty; L C Coates
Journal:  Rheumatol Ther       Date:  2022-01-15

2.  TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).

Authors:  Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.